Table of Contents Author Guidelines Submit a Manuscript
Infectious Diseases in Obstetrics and Gynecology
Volume 2008, Article ID 219672, 5 pages
Research Article

Chlamydia trachomatis Serology in Women with and without Ovarian Cancer

1School of Public Health, University of Texas, Houston, TX 77030, USA
2UBC Centre for Disease Control, Vancouver, BC, Canada V5Z 4R4
3Graduate School of Public Health and Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA
4Department of Epidemiology, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY 14214, USA
5Magee-Women's Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA

Received 10 January 2008; Revised 7 August 2008; Accepted 20 October 2008

Academic Editor: Jeanne Marrazzo

Copyright © 2008 Roberta B. Ness et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Pelvic inflammation has been implicated in the genesis of ovarian cancer. We conducted serologic measurements of Chlamydia trachomatis antibodies as a surrogate marker of chlamydial pelvic inflammatory disease. Women with ovarian cancer ( 𝑛 = 5 2 1 ) and population-based controls ( 𝑛 = 7 6 6 ) were tested. IgG antibodies to serovar D of chlamydia elementary bodies (EBs) were detected using an ELISA assay. The odds of having ovarian cancer among women with the highest titers (≥0.40 OD units) were 0.6 (95% CI 0.4–0.9). These data do not support our earlier finding of elevated titers for antibodies to C. trachomatis among women with ovarian cancer.